Genentech's Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
Genentech's Enspryng Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
REPEAT - Drilling at Swanson Gold Deposit Confirms Large-Scale Gold Discovery with 1.18 g/t Au over 255.04 metres and 1.65 g/t Au over 136.01 metres
